Compare NTST & SANA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTST | SANA |
|---|---|---|
| Founded | 2019 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2020 | 2021 |
| Metric | NTST | SANA |
|---|---|---|
| Price | $18.36 | $4.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 6 |
| Target Price | ★ $20.18 | $7.83 |
| AVG Volume (30 Days) | 1.2M | ★ 2.5M |
| Earning Date | 02-10-2026 | 03-16-2026 |
| Dividend Yield | ★ 4.70% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.00 | N/A |
| Revenue | ★ $186,359,000.00 | N/A |
| Revenue This Year | $18.52 | N/A |
| Revenue Next Year | $12.04 | N/A |
| P/E Ratio | $8,298.23 | ★ N/A |
| Revenue Growth | ★ 19.39 | N/A |
| 52 Week Low | $13.74 | $1.26 |
| 52 Week High | $19.64 | $6.55 |
| Indicator | NTST | SANA |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 56.55 |
| Support Level | $18.04 | $4.36 |
| Resistance Level | $18.64 | $5.20 |
| Average True Range (ATR) | 0.41 | 0.34 |
| MACD | 0.09 | 0.03 |
| Stochastic Oscillator | 80.78 | 67.39 |
Netstreit Corp is an internally managed real estate investment trust. The company acquires, owns, and manages single-tenant, retail commercial real estate subject to long-term net leases with high-credit quality tenants across the United States. It focuses on tenants in industries where a physical location is critical to the generation of sales and profits, with a focus on necessity goods and essential services in the retail sector, including home improvement, auto parts, drug stores and pharmacies, general retail, grocers, convenience stores, discount stores, and quick-service restaurants. Majorily operates in U.S. States and Other counties, and derives maximum of revenue from USA.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.